ArticleMicrobial cell factories2021
Fermentative production of enantiopure (S)-linalool using a metabolically engineered Pantoea ananatis.
Article in Microbial cell factories, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- Cycloparaffin-rich high density sustainable aviation fuel: pathways from terpenes, terpenoids, and plant oils.RSC advances · 2026Review
- Engineering an ATP-saving mevalonate pathway for high-efficiency S-(+)-linalool production inSynthetic and systems biotechnology · 2026Article
- Origin of replication discovery for environmentally isolatediScience · 2026Article
- Expanding the Terpene Universe: Synthetic Biology and Non-Natural Chemistry in Engineered Microorganisms.Molecules (Basel, Switzerland) · 2025Review
- Two-Phase Fermentation Systems for Microbial Production of Plant-Derived Terpenes.Molecules (Basel, Switzerland) · 2024Review
- Boosting Geranyl Diphosphate Synthesis for Linalool Production in Engineered Yarrowia lipolytica.Applied biochemistry and biotechnology · 2024Article
- Genomic delineation and description of species and within-species lineages in the genusFrontiers in microbiology · 2023Article
- Natural Compounds in the Battle against Microorganisms-Linalool.Molecules (Basel, Switzerland) · 2022Review
- Enhancement of linalool production in Saccharomyces cerevisiae by utilizing isopentenol utilization pathway.Microbial cell factories · 2022Article
- Solvent-free dehydration, cyclization, and hydrogenation of linalool with a dual heterogeneous catalyst system to generate a high-performance sustainable aviation fuel.Communications chemistry · 2022Article
- Engineering for life in toxicity: Key to industrializing microbial synthesis of high energy density fuels.Engineering microbiology · 2022Review
- Microbial Production Potential ofMicroorganisms · 2022Review
- Practical genetic control strategies for industrial bioprocesses.Journal of industrial microbiology & biotechnology · 2022Review
- Toward improved terpenoids biosynthesis: strategies to enhance the capabilities of cell factories.Bioresources and bioprocessing · 2022Review
- Bioproduction of Linalool From Paper Mill Waste.Frontiers in bioengineering and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLinalool, an acyclic monoterpene alcohol, is extensively used in the flavor and fragrance industries and exists as two enantiomers, (S)- and (R)-linalool, which have different odors and biological properties. Linalool extraction from natural plant tissues suffers from low product yield. Although linalool can also be chemically synthesized, its enantioselective production is difficult. Microbial production of terpenes has recently emerged as a novel, environmental-friendly alternative. Stereoselective production can also be achieved using this approach via enzymatic reactions. We previously succeeded in producing enantiopure (S)-linalool using a metabolically engineered Pantoea ananatis, a member of the Enterobacteriaceae family of bacteria, via the heterologous mevalonate pathway with the highest linalool titer ever reported from engineered microbes.
resultsHere, we genetically modified a previously developed P. ananatis strain expressing the (S)-linalool synthase (AaLINS) from Actinidia arguta to further improve (S)-linalool production. AaLINS was mostly expressed as an insoluble form in P. ananatis; its soluble expression level was increased by N-terminal fusion of a halophilic β-lactamase from Chromohalobacter sp. 560 with hexahistidine. Furthermore, in combination with elevation of the precursor supply via the mevalonate pathway, the (S)-linalool titer was increased approximately 1.4-fold (4.7 ± 0.3 g/L) in comparison with the original strain (3.4 ± 0.2 g/L) in test-tube cultivation with an aqueous-organic biphasic fermentation system using isopropyl myristate as the organic solvent for in situ extraction of cytotoxic and semi-volatile (S)-linalool. The most productive strain, IP04S/pBLAAaLINS-ispA*, produced 10.9 g/L of (S)-linalool in "dual-phase" fed-batch fermentation, which was divided into a growth-phase and a subsequent production-phase. Thus far, this is the highest reported titer in the production of not only linalool but also all monoterpenes using microbes.
conclusionsThis study demonstrates the potential of our metabolically engineered P. ananatis strain as a platform for economically feasible (S)-linalool production and provides insights into the stereoselective production of terpenes with high efficiency. This system is an environmentally friendly and economically valuable (S)-linalool production alternative. Mass production of enantiopure (S)-linalool can also lead to accurate assessment of its biological properties by providing an enantiopure substrate for study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.